Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice

Previous Epstein-Barr virus (EBV) prophylactic vaccines based on the major surface glycoprotein gp350/220 as an immunogen have failed to block viral infection in humans, suggesting a need to target other viral envelope glycoproteins. In this study, we reasoned that incorporating gH/gL or gB, critica...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Elizabeth M., Foley, Joslyn, Tison, Timelia, Silva, Rute, Ogembo, Javier Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386682/
https://www.ncbi.nlm.nih.gov/pubmed/27926486
http://dx.doi.org/10.18632/oncotarget.13770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386682/
https://www.ncbi.nlm.nih.gov/pubmed/27926486
http://dx.doi.org/10.18632/oncotarget.13770

Ejemplares similares